Nothing Special   »   [go: up one dir, main page]

PT3540062T - Permuta de cassete de região variável de imunoglobulina - Google Patents

Permuta de cassete de região variável de imunoglobulina

Info

Publication number
PT3540062T
PT3540062T PT191691351T PT19169135T PT3540062T PT 3540062 T PT3540062 T PT 3540062T PT 191691351 T PT191691351 T PT 191691351T PT 19169135 T PT19169135 T PT 19169135T PT 3540062 T PT3540062 T PT 3540062T
Authority
PT
Portugal
Prior art keywords
variable region
immunoglobulin variable
cassette exchange
region cassette
exchange
Prior art date
Application number
PT191691351T
Other languages
English (en)
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36407771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3540062(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humanigen Inc filed Critical Humanigen Inc
Publication of PT3540062T publication Critical patent/PT3540062T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT191691351T 2004-11-16 2005-11-16 Permuta de cassete de região variável de imunoglobulina PT3540062T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62858104P 2004-11-16 2004-11-16

Publications (1)

Publication Number Publication Date
PT3540062T true PT3540062T (pt) 2021-07-06

Family

ID=36407771

Family Applications (2)

Application Number Title Priority Date Filing Date
PT10014128T PT2343380T (pt) 2004-11-16 2005-11-16 Permuta de cassetes da região variável de imunoglobulina
PT191691351T PT3540062T (pt) 2004-11-16 2005-11-16 Permuta de cassete de região variável de imunoglobulina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT10014128T PT2343380T (pt) 2004-11-16 2005-11-16 Permuta de cassetes da região variável de imunoglobulina

Country Status (10)

Country Link
US (2) US20060134098A1 (pt)
EP (3) EP3540062B1 (pt)
JP (1) JP2008520586A (pt)
AU (1) AU2005306502B2 (pt)
CA (1) CA2587158C (pt)
DK (2) DK2343380T3 (pt)
ES (3) ES2881353T3 (pt)
PL (2) PL3540062T3 (pt)
PT (2) PT2343380T (pt)
WO (1) WO2006055778A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
CA2587158C (en) 2004-11-16 2016-01-12 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US8911733B2 (en) * 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
JP2009538924A (ja) 2006-06-01 2009-11-12 エラン ファーマシューティカルズ，インコーポレイテッド Ａｐｐの神経活性断片
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
CA2670288C (en) 2006-11-21 2015-10-27 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EP2126105A4 (en) 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
EP3199180B1 (en) * 2007-03-08 2022-01-05 Humanigen, Inc. Epha3 antibodies for the treatment of solid tumors
CA2680344A1 (en) * 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
WO2009012401A1 (en) * 2007-07-17 2009-01-22 Irm Llc Antagonist antibodies of protease activated receptor-1 (par1)
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009073631A2 (en) 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
PT2281078E (pt) 2008-04-24 2015-02-05 Dyax Corp Bibliotecas de pacotes genéticos compreendendo desenhos de novas cdr1, cdr2, e cdr3 de hc e novas cdr1, cr2, e cdr3 de lc
NZ588850A (en) * 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
EP2393515A1 (en) 2009-02-04 2011-12-14 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
WO2010102244A1 (en) 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
WO2010135558A1 (en) * 2009-05-20 2010-11-25 Novimmune S.A. Systhetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
WO2011053465A1 (en) 2009-10-14 2011-05-05 Kalobios Pharmaceuticals, Inc. Antibodies to epha3
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JP5686817B2 (ja) 2009-12-22 2015-03-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 配列依存性の凝集
BR112012020790B1 (pt) 2010-02-18 2021-09-28 The Regents Of The University Of California Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica
US20110245100A1 (en) * 2010-04-02 2011-10-06 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest
CA2827091A1 (en) 2011-02-11 2012-08-16 Irm Llc Pcsk9 antagonists
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
EP2764021A2 (en) * 2011-10-05 2014-08-13 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid
CA2853637C (en) 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2015089117A1 (en) 2013-12-09 2015-06-18 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
EP4014995A1 (en) 2014-02-28 2022-06-22 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2987797A1 (en) 2015-06-17 2016-12-22 Christopher Robert Bebbington Methods and compositions for treating fibrotic diseases
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
PE20181358A1 (es) 2015-12-04 2018-08-22 Novartis Ag Composiciones de anticuerpo injertado con citoquina y metodos para su uso en inmunorregulacion
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
WO2018053032A1 (en) 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US11203638B2 (en) 2017-05-05 2021-12-21 Allakos Inc. Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
SG11202106498XA (en) 2018-12-26 2021-07-29 Xilio Development Inc Anti-ctla4 antibodies and methods of use thereof
WO2022187270A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022187272A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3742105A (en) 1970-05-05 1973-06-26 S Kuroda Method for producing a seamless tubing
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
AU634186B2 (en) * 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
DK1034298T3 (da) * 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6875590B2 (en) 2000-06-05 2005-04-05 Corixa Corporation Leader peptides for enhancing secretion of recombinant protein from a host cell
WO2002000005A1 (en) 2000-06-21 2002-01-03 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
CA2491864C (en) * 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003099999A2 (en) * 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050008625A1 (en) * 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
EP2465872A3 (en) 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
CA2587158C (en) 2004-11-16 2016-01-12 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof

Also Published As

Publication number Publication date
EP1824987B1 (en) 2013-08-21
EP1824987A4 (en) 2008-03-19
PT2343380T (pt) 2019-09-18
CA2587158C (en) 2016-01-12
US20060134098A1 (en) 2006-06-22
ES2881353T3 (es) 2021-11-29
DK3540062T3 (da) 2021-06-28
PL3540062T3 (pl) 2021-12-27
US20160102152A1 (en) 2016-04-14
EP2343380B1 (en) 2019-06-12
AU2005306502A1 (en) 2006-05-26
AU2005306502B2 (en) 2012-11-15
WO2006055778A3 (en) 2006-11-23
CA2587158A1 (en) 2006-05-26
US10919983B2 (en) 2021-02-16
JP2008520586A (ja) 2008-06-19
EP1824987A2 (en) 2007-08-29
ES2744149T3 (es) 2020-02-21
PL2343380T3 (pl) 2020-03-31
DK2343380T3 (da) 2019-09-09
ES2429541T3 (es) 2013-11-15
EP3540062B1 (en) 2021-05-12
EP2343380A1 (en) 2011-07-13
EP3540062A1 (en) 2019-09-18
WO2006055778A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
PL2343380T3 (pl) Wymiana kasety dla regionu zmiennego immunoglobuliny
TWI307630B (en) Immunoglobulins
TWI365746B (en) Immunoglobulins
EP1789217A4 (en) SANDWICH FINS
IL183861A0 (en) Temperature compensanon
GB0423303D0 (en) No title
GB0426735D0 (en) The mobile e-commerce exchange
GB0417789D0 (en) Access control
GB0407231D0 (en) Variable lens
GB0423010D0 (en) Cassette
GB0421997D0 (en) Film
EP1718749A4 (en) ANTI-AF-20 HUMANIZED MONOCLONAL ANTIBODY
ZA200504313B (en) Cassette assembly
ZA200610612B (en) Immunoglobulins
GB2410544B (en) Radiator cover
GB0302699D0 (en) Immunoglobulin
GB0417492D0 (en) Radiator covers
GB0407197D0 (en) Immunoglobulins
GB0417389D0 (en) No title
GB0405968D0 (en) Neat heat
GB0513766D0 (en) Immunoglobulins
PL1635122T3 (pl) Grzejnik
GB0407193D0 (en) Immunoglobulins
GB0423675D0 (en) Immunoglobulins
GB0401247D0 (en) Router cassette